CN100415871C - 卡他摩拉克菌外膜蛋白—106多肽及其基因序列和用途 - Google Patents

卡他摩拉克菌外膜蛋白—106多肽及其基因序列和用途 Download PDF

Info

Publication number
CN100415871C
CN100415871C CNB2005100924509A CN200510092450A CN100415871C CN 100415871 C CN100415871 C CN 100415871C CN B2005100924509 A CNB2005100924509 A CN B2005100924509A CN 200510092450 A CN200510092450 A CN 200510092450A CN 100415871 C CN100415871 C CN 100415871C
Authority
CN
China
Prior art keywords
omp106
polypeptide
catarrhalis
polypeptides
atcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100924509A
Other languages
English (en)
Chinese (zh)
Other versions
CN1800359A (zh
Inventor
K·图克尔
L·普罗斯拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Antex Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biologics Inc filed Critical Antex Biologics Inc
Publication of CN1800359A publication Critical patent/CN1800359A/zh
Application granted granted Critical
Publication of CN100415871C publication Critical patent/CN100415871C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNB2005100924509A 1996-05-03 1997-04-28 卡他摩拉克菌外膜蛋白—106多肽及其基因序列和用途 Expired - Fee Related CN100415871C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US08/642712 1996-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB971959900A Division CN1222618C (zh) 1996-05-03 1997-04-28 卡他摩拉克菌外膜蛋白－106多肽及其基因序列和用途

Publications (2)

Publication Number Publication Date
CN1800359A CN1800359A (zh) 2006-07-12
CN100415871C true CN100415871C (zh) 2008-09-03

Family

ID=24577687

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100924509A Expired - Fee Related CN100415871C (zh) 1996-05-03 1997-04-28 卡他摩拉克菌外膜蛋白—106多肽及其基因序列和用途
CNB971959900A Expired - Fee Related CN1222618C (zh) 1996-05-03 1997-04-28 卡他摩拉克菌外膜蛋白－106多肽及其基因序列和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB971959900A Expired - Fee Related CN1222618C (zh) 1996-05-03 1997-04-28 卡他摩拉克菌外膜蛋白－106多肽及其基因序列和用途

Country Status (25)

Country Link
US (6) US7341727B1 (enExample)
EP (1) EP0900025B1 (enExample)
JP (2) JP4401437B2 (enExample)
CN (2) CN100415871C (enExample)
AR (1) AR006999A1 (enExample)
AT (1) ATE244016T1 (enExample)
AU (1) AU723528B2 (enExample)
BG (1) BG64832B1 (enExample)
BR (1) BR9711090A (enExample)
CA (1) CA2253636C (enExample)
CZ (1) CZ298034B6 (enExample)
DE (1) DE69723254T2 (enExample)
EA (1) EA002743B1 (enExample)
EE (1) EE04684B1 (enExample)
ES (1) ES2202624T3 (enExample)
GE (1) GEP20022695B (enExample)
HU (1) HU223004B1 (enExample)
NO (2) NO324816B1 (enExample)
NZ (1) NZ332896A (enExample)
PL (3) PL189375B1 (enExample)
SK (1) SK284812B6 (enExample)
TW (1) TW541314B (enExample)
UA (1) UA68332C2 (enExample)
WO (1) WO1997041731A1 (enExample)
ZA (1) ZA973809B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) * 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
DE60039108D1 (de) * 1999-05-24 2008-07-17 Glaxosmithkline Biolog Sa Neue verbindungen aus moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
EP1214339B1 (en) * 1999-09-14 2007-08-01 GlaxoSmithKline Biologicals S.A. Polypeptides from moraxella (branhamella) catarrhalis
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
AU2003260357B2 (en) 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DK2384765T3 (en) 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP5275814B2 (ja) 2006-01-17 2013-08-28 フオルスレン，アルネ 新規表面露出ヘモフィルス・インフルエンザ（ＨＡＥＭＯＰＨＩＬＵＳＩＮＦＬＵＥＮＺＡＥ）タンパク質（タンパク質Ｅ；ｐＥ）
US20100092471A1 (en) * 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
DK2175851T3 (da) 2007-07-12 2013-07-15 Oral Health Australia Pty Ltd Biofilmbehandling
JP2010532766A (ja) 2007-07-12 2010-10-14 オーラル ヘルス オーストラリア ピーティーワイ リミテッド バイオフィルムに対する免疫学的治療
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
WO2010022463A1 (en) 2008-08-29 2010-03-04 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
JP5701894B2 (ja) 2009-11-23 2015-04-15 サイヴェク・インコーポレイテッド アッセイを行う方法及び装置
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
WO2013134744A2 (en) 2012-03-08 2013-09-12 Cyvek, Inc Microfluidic assay assemblies and methods of manufacture
US10022696B2 (en) 2009-11-23 2018-07-17 Cyvek, Inc. Microfluidic assay systems employing micro-particles and methods of manufacture
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012022669A2 (pt) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
US8501197B2 (en) 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
JP5978287B2 (ja) 2011-03-22 2016-08-24 サイヴェク・インコーポレイテッド マイクロ流体装置並びに製造及び使用の方法
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
MX393066B (es) 2016-04-18 2025-03-24 Celldex Therapeutics Inc Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3630176A1 (en) 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
WO2022217019A1 (en) 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
WO1993003761A1 (en) * 1991-08-15 1993-03-04 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) * 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) * 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
WO1993003761A1 (en) * 1991-08-15 1993-03-04 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Purification and characterization of ahigh-molecular-weightouter membrane protein of Moraxella(Branhamella)catarrhalis.. K L Klingman et al.Infection and Immunity,Vol.62 No.4. 1994 *

Also Published As

Publication number Publication date
BR9711090A (pt) 1999-08-17
PL189375B1 (pl) 2005-07-29
AU3118097A (en) 1997-11-26
EP0900025A4 (en) 2000-01-05
US20100021492A1 (en) 2010-01-28
HUP9902695A2 (hu) 1999-12-28
CZ352498A3 (cs) 1999-06-16
NO324816B1 (no) 2007-12-10
US20080145916A1 (en) 2008-06-19
SK284812B6 (sk) 2005-12-01
WO1997041731A1 (en) 1997-11-13
EE04684B1 (et) 2006-08-15
GEP20022695B (en) 2002-05-27
CZ298034B6 (cs) 2007-05-30
CA2253636C (en) 2003-04-22
HK1095358A1 (zh) 2007-05-04
ATE244016T1 (de) 2003-07-15
EA002743B1 (ru) 2002-08-29
US7341727B1 (en) 2008-03-11
EP0900025A1 (en) 1999-03-10
EA199800973A1 (ru) 1999-06-24
US20020177200A1 (en) 2002-11-28
NO985113D0 (no) 1998-11-02
NZ332896A (en) 2000-05-26
ES2202624T3 (es) 2004-04-01
PL189374B1 (pl) 2005-07-29
HUP9902695A3 (en) 2001-02-28
NO20063711L (no) 1998-12-28
US20070087019A1 (en) 2007-04-19
US7128910B2 (en) 2006-10-31
JP4401437B2 (ja) 2010-01-20
US7914795B2 (en) 2011-03-29
ZA973809B (en) 1997-12-01
AR006999A1 (es) 1999-10-13
SK150998A3 (en) 1999-05-07
BG64832B1 (bg) 2006-06-30
EE9800373A (et) 1999-04-15
DE69723254T2 (de) 2004-04-22
CN1222618C (zh) 2005-10-12
JP2000510696A (ja) 2000-08-22
AU723528B2 (en) 2000-08-31
HU223004B1 (hu) 2004-03-01
CA2253636A1 (en) 1997-11-13
US7576179B2 (en) 2009-08-18
US6214981B1 (en) 2001-04-10
EP0900025B1 (en) 2003-07-02
BG102983A (en) 2000-05-31
JP2008161194A (ja) 2008-07-17
CN1800359A (zh) 2006-07-12
DE69723254D1 (de) 2003-08-07
CN1223549A (zh) 1999-07-21
PL330935A1 (en) 1999-06-07
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
PL189995B1 (pl) 2005-10-31
UA68332C2 (en) 2004-08-16
HK1021299A1 (en) 2000-06-09

Similar Documents

Publication Publication Date Title
CN100415871C (zh) 卡他摩拉克菌外膜蛋白—106多肽及其基因序列和用途
US7846451B2 (en) Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
KR100500000B1 (ko) 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
HK1095358B (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1095358

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1095358

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080903

Termination date: 20110428